Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Inhibrx Biosciences (INBX) Interest Expenses (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Interest Expenses for 3 consecutive years, with $3.2 million as the latest value for Q4 2025.

  • Quarterly Interest Expenses changed N/A to $3.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $12.2 million through Dec 2025, down 9.6% year-over-year, with the annual reading at $12.2 million for FY2025, 9.6% down from the prior year.
  • Interest Expenses for Q4 2025 was $3.2 million at Inhibrx Biosciences, roughly flat from $3.2 million in the prior quarter.
  • The five-year high for Interest Expenses was $8.2 million in Q4 2023, with the low at $2.7 million in Q1 2025.
  • Average Interest Expenses over 3 years is $5.6 million, with a median of $5.4 million recorded in 2024.
  • The sharpest move saw Interest Expenses plummeted 32.18% in 2024, then plummeted 66.92% in 2025.
  • Over 3 years, Interest Expenses stood at $8.2 million in 2023, then tumbled by 34.8% to $5.4 million in 2024, then plummeted by 40.59% to $3.2 million in 2025.
  • According to Business Quant data, Interest Expenses over the past three periods came in at $3.2 million, $3.2 million, and $3.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.